Validation of SNHG11 as a prognostic and predictive biomarker for anti-EGFR benefit in colorectal cancer using real-world data.

作者：Michela Bartolini, Yasmine Baca, Joanne Xiu, Shivani Soni, Pooja Mittal, Unnati Hemant Shah, Lesly Torres-Gonzalez, Steve Soto Trujillo, Yitzhar Efraim Goretsky, Sandra Algaze, Wu Zhang, Yan Yang, Joshua Millstein, Jae Ho-Lo, Richard M. Goldberg, Anthony F. Shields, Andreas Seeber, Alberto Puccini, Heinz-Josef Lenz · 发表于：Journal of Clinical Oncology · 年份：2026 · DOI：10.1200/jco.2026.44.16_suppl.3138 · 研究领域：Cancer-related molecular mechanisms research、Colorectal Cancer Treatments and Studies、Ferroptosis and cancer prognosis

3138 Background: Long non-coding RNAs (lncRNAs) regulate colorectal cancer (CRC) initiation, progression, and therapeutic response through interactions with oncogenic and microenvironmental pathways. SNHG11 has been implicated in CRC through epigenetic and c-Myc–driven transcriptional programs. In CALGB/SWOG 80405, higher tumor SNHG11 expression correlated with improved outcomes, particularly anti-EGFR therapy (Bartolini 2025, ASCO 43; 16_suppl). We comprehensively evaluated molecular correlates with SNHG11 and validated the prognostic and predictive value in an independent real-world CRC cohort. Methods: In total, 15,456 CRC underwent DNA (592-gene or whole exome) and RNA (whole transcriptome) sequencing at Caris Life Sciences. Tumors were stratified by SNHG11 expression quartiles, comparing low (Q1) vs high (Q4). CMS classification was assessed using RNAseq. Associations were assessed using X 2 /Fisher’s exact with p-values adjusted for multiple comparisons (q<0.05). Clinical outcome was obtained from insurance claims. Overall survival (OS) was calculated from tissue collection to last contact and time-on-treatment (ToT) from treatment start to end. Cox proportional hazards model generated hazard ratio (HR) and log-rank p-values. Results: SNHG11 Q1 tumors were associated with higher right-sided prevalence (28% vs 18%, p<0.001), lower left-sided prevalence (50% vs 62%, p<0.001), and older age than Q4 (64 vs 62, p<0.001). Consistent with the findings in CALGB/SWOG...